Accuracy of early detection of colorectal tumours by stool methylation markers: A meta-analysis

Zhang, Hu; Qi, Jian; Wu, Yaqiong; Zhang, Ping; Jiang, Jun; Wang, Qi-Xian; Zhu, Yufan

doi:10.3748/wjg.v20.i38.14040

Cited by 27 publications

(23 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Zhang et al 69 evaluated the accuracy of gene methylation analysis of DNA in stool samples for diagnosing CRC. They included 37 articles that comprised 4484 patients.…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Performance of Stool DNA Testing for Colorectal Cancer

Zhai

Xu²,

Zhang³

et al. 2016

Medicine

View full text Add to dashboard Cite

This meta-analysis was designed to evaluate the diagnostic performance of stool DNA testing for colorectal cancer (CRC) and compare the performance between single-gene and multiple-gene tests.MEDLINE, Cochrane, EMBASE databases were searched using keywords colorectal cancers, stool/fecal, sensitivity, specificity, DNA, and screening. Sensitivity analysis, quality assessments, and performance bias were performed for the included studies.Fifty-three studies were included in the analysis with a total sample size of 7524 patients. The studies were heterogeneous with regard to the genes being analyzed for fecal genetic biomarkers of CRC, as well as the laboratory methods being used for each assay. The sensitivity of the different assays ranged from 2% to 100% and the specificity ranged from 81% to 100%. The meta-analysis found that the pooled sensitivities for single- and multigene assays were 48.0% and 77.8%, respectively, while the pooled specificities were 97.0% and 92.7%. Receiver operator curves and diagnostic odds ratios showed no significant difference between both tests with regard to sensitivity or specificity.This meta-analysis revealed that using assays that evaluated multiple genes compared with single-gene assays did not increase the sensitivity or specificity of stool DNA testing in detecting CRC.

show abstract

“…Zhang et al 69 evaluated the accuracy of gene methylation analysis of DNA in stool samples for diagnosing CRC. They included 37 articles that comprised 4484 patients.…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Performance of Stool DNA Testing for Colorectal Cancer

Zhai

Xu²,

Zhang³

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…A systematic meta-analysis has revealed that the pooled sensitivity and specificity of methylated SFRP2 are 0.71 and 0.94, respectively 41 . SFRP2 methylation is therefore a promising biomarker for CRC screen 42 . The DNA stool test of SFRP1hypermethylation also achieves a sensitivity of 89% and specificity of 86% in colorectal neoplasia detection 35 .…”

Section: Multiple Dna Methylation Biomarkersmentioning

confidence: 99%

DNA methylation assay for colorectal carcinoma

Chen¹,

Wang

Chen

2017

Cancer Biology &Amp; Medicine

View full text Add to dashboard Cite

Colorectal carcinoma (CRC) is a common cause of morbidity and mortality worldwide. Two pathogenic pathways are involved in the development of adenoma to CRC. The first pathway involvesAPC/β-catenin characterized by chromosomal instability resulting in the accumulation of mutations. The second pathway is characterized by lesions inDNA mismatch repair genes. Aberrant DNA methylation in selected gene promoters has emerged as a new epigenetic pathway in CRC development. CRC screening is the most efficient strategy to reduce death. Specific DNA methylation events occur in multistep carcinogenesis. Epigenetic gene silencing is a causative factor of CRC development. DNA methylations have been extensively examined in stool from CRC and precursor lesions. Many methylated genes have been described in CRC and adenoma, although no definite DNA methylation biomarkers panel has been established. Multiple DNA methylation biomarkers, including secreted frizzled-related protein 2, secreted frizzled-related protein 1, tissue factor pathway inhibitor 2, vimentin, and methylguanine DNA methyltransferase, have been further investigated, and observations have revealed that DNA methylation biomarkers exhibit with high sensitivity and specificity. These markers may also be used to diagnose CRC and adenoma in early stages. Real time polymerase chain reaction (qPCR) is sensitive, scalable, specific, reliable, time saving, and cost effective. Stool exfoliated markers provide advantages, including sensitivity and specificity. A stool qPCR methylation test may also be an enhanced tool for CRC and adenoma screening.

show abstract

“…La letteratura riporta pochi report-studi che attribuiscono al test una sensibilità vicina al 90-100%, mentre numerosi lavori indicano valori più bassi non superiori al 50% [46].…”

Section: Raccomandazioni Per Lo Screeningunclassified

Tumore del colon retto: percorsi diagnostici sulla base di linee guida internazionali

et al. 2016

View full text Add to dashboard Cite

Riassunto Il tumore del colon retto (CCR) rappresenta ancora oggi una delle neoplasie più importanti, con indici di mortalità e progressione metastatica della malattia legati alle caratteristiche biologiche e strutturali del tumore primario. A fronte di un aumento complessivo dell'incidenza si è Per il Gruppo di Studio in registrata una riduzione della mortalità di quasi il 35% negli ultimi due decenni. Al calo della mortalità hanno dato un contributo notevole gli interventi di medicina predittiva e preventiva che si avvalgono di una serie di strumenti diagnostici e device chirurgici esplorativi (endoscopia) che consentono diagnosi molto precoce e interventi ambulatoriali sulle lesioni displasiche e poliposiche, evitando la trasformazione neoplastica e l'invasività della massa tumorale. La presente review descrive i progressi ottenuti soprattutto negli interventi di screening di massa sulla popolazione, per i quali riveste notevole importanza la ricerca del sangue occulto fecale (SOF) che permette l'individuazione di zone di microsanguinamento nell'alveo colico, possibile sentinella di un processo neoplastico. Il SOF ha riscosso un notevole successo negli ultimi tempi e, nelle Regioni in cui il processo di screening è ormai collaudato e consolidato, ha permesso di abbattere notevolmente il rischio di malattia metastatica e l'indice di mortalità associato. Un altro passo avanti molto importante è rappresentato dall'utilizzo di moderne tecniche di indagine molecolare che consentono di analizzare mutazioni e lesioni epigenetiche a carico di geni coinvolti nel meccanismo patogenetico di induzione tumorale (analisi del DNA fecale) come strumento ad alta sensibilità e specificità per il riconoscimento delle microlesioni neoplastiche. Nel presente lavoro viene infine dato spazio al ruolo che vari marcatori sierologici come il CEA e il Ca 19.9 rivestono

show abstract

Accuracy of early detection of colorectal tumours by stool methylation markers: A meta-analysis

Abstract: Stool-based DNA testing may be useful for noninvasively diagnosing colorectal tumours and SFRP2 methylation is a promising marker that has great potential in early CRC diagnosis.

Cited by 27 publications

References 46 publications

The Diagnostic Performance of Stool DNA Testing for Colorectal Cancer

The Diagnostic Performance of Stool DNA Testing for Colorectal Cancer

DNA methylation assay for colorectal carcinoma

Tumore del colon retto: percorsi diagnostici sulla base di linee guida internazionali

Contact Info

Product

Resources

About